PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gefapixant→

Gefapixant PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1015787-98-0
Molecular formula
C14H19N5O4S
Molecular weight
353.4 g/mol
Drug class
Selective P2X3 receptor antagonistnon-opioid antitussive
Mechanism of action
Selectively antagonises ATP-gated P2X3 receptors, with some activity at P2X2/3 receptors, on airway vagal sensory C-fibres. This reduces ATP-mediated sensory-nerve activation and the urge-to-cough signalling pathway.
Indications / reported uses
  • Treatment of refractory or unexplained chronic cough in adults under the EU-authorised indication; local availability and authorisation vary by jurisdiction

Sources: EMA EPAR — Lyfnua · EMA product information (mechanism and indication) · UK SmPC — Lyfnua 45 mg · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Gefapixant PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gefapixant Permitted Daily Exposure (PDE) report (the Gefapixant PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gefapixant Occupational Exposure Limit (OEL) report (the Gefapixant OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.